Regenerex Pharma (RGPX) Financials
Newest figures come from the 10-KT for Q4 FY2025, filed Aug 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RGPX SEC filings page.
This page shows Regenerex Pharma Inc (RGPX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
RGPX operates with liabilities far above assets, while financing inflows offset cash losses and operating costs remain heavy.
The cash-versus-accounting-loss gap is substantial: in FY2025, net loss was$2.5M against operating cash outflow of$1.6M , meaning some reported costs did not immediately consume cash. That gap was wider in FY2024, when net loss was$3.5M against operating cash outflow of$458K , so cash usage did not track reported loss one-for-one.
FY2025 current assets of
FY2025 financing cash flow of
Financial Health Signals
We do not publish a peer-relative financial health score for Regenerex Pharma Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Regenerex Pharma Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Regenerex Pharma Inc reported a net loss of $2.5M while operations used $1.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Regenerex Pharma Inc reported an operating loss of $1.8M against $320K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Regenerex Pharma Inc held $11K in cash as of Q4 2025; no long-term debt figure is on record for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
RGPX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-KT | Q2'2610-Q | Q1'2610-Q | Q4'2510-KT | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $136K | N/A | N/A | $17K | N/A | N/A | N/A |
| SG&A Expenses | N/A | $650K+151.7% | $634K+149.2% | $357K | $294K+22.9% | $258K-33.0% | $254K+55.8% | N/A |
| Operating Income | N/A | -$787Kn/m | -$634Kn/m | N/A | -$312Kn/m | -$258Kn/m | -$254Kn/m | -$280K |
| EBITDA | N/A | -$786Kn/m | -$633Kn/m | N/A | -$311Kn/m | -$257Kn/m | -$252Kn/m | N/A |
| Interest Expense | N/A | $23K-91.5% | $24K+5.7% | N/A | $27K+33.6% | $266K+1244.2% | $22K+20.7% | N/A |
| Income Tax | N/A | -$50 | -$113 | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$814Kn/m | -$664Kn/m | -$1.4Mn/m | -$315Kn/m | -$530Kn/m | -$273Kn/m | -$293K |
| EPS (Basic) | N/A | $0.00n/m | $0.00n/m | -$0.01n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EPS (Diluted), Diluted Shares (Avg).
RGPX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-KT | Q2'2610-Q | Q1'2610-Q | Q4'2510-KT | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $512K-33.2% | $618K-2.4% | $763K+4.7% | $1.3M+64.8% | $647K-24.1% | $633K-32.1% | $729K-29.9% | $767K+11624.7% |
| Current Assets | $23K+686.2% | $48K+2539.2% | $193K+8074.8% | $653K+22337.3% | $988-89.4% | $2K-90.5% | $2K-97.4% | $3K+156.6% |
| Cash & Equivalents | $11K+2870.2% | $12K+3865.6% | $172Kn/m | $653K+175444.4% | $338-95.7% | $294-95.2% | $0-100.0% | $372-67.2% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $5.5M+14.2% | $5.3M-1.4% | $5.3M+5.3% | $5.4M+12.2% | $5.7M+20.6% | $5.4M+18.0% | $5.0M+137.5% | $4.8M+327.5% |
| Current Liabilities | $5.2M+34.5% | $4.9M+1.5% | $4.9M+9.9% | $4.9M+28.1% | $5.2M+45.0% | $4.9M+45.3% | $4.4M+450.5% | $3.8M+394.8% |
| Non-Current Liabilities | $345K-65.0% | $393K-27.2% | $459K-27.0% | $496K-49.7% | $541K-53.7% | $540K-56.1% | $629K-52.4% | $985K+179.3% |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $184K |
| Total Equity | -$5.0Mn/m | -$4.7Mn/m | -$4.5Mn/m | -$4.2Mn/m | -$5.1Mn/m | -$4.8Mn/m | -$4.3Mn/m | -$4.1Mn/m |
| Retained Earnings | -$10.7Mn/m | -$9.6Mn/m | -$8.8Mn/m | -$8.1Mn/m | -$6.7Mn/m | -$6.4Mn/m | -$5.9Mn/m | -$5.6Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
RGPX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-KT | Q2'2610-Q | Q1'2610-Q | Q4'2510-KT | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$250Kn/m | -$519Kn/m | -$478Kn/m | -$1.3Mn/m | -$159Kn/m | -$127Kn/m | -$55Kn/m | -$64Kn/m |
| Depreciation & Amortization | $1K-37.7% | $1K-7.1% | $1K-32.2% | $426-77.1% | $851-54.8% | $1K-33.3% | $2K+20.2% | $2K-38.6% |
| Stock-Based Compensation | N/A | N/A | $257K+1124.6% | N/A | N/A | N/A | $21K-39.2% | N/A |
| Investing Cash Flow | $38Kn/m | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m |
| Financing Cash Flow | $211K+270.6% | $398K+213.2% | -$3K-104.8% | $1.9M+3304.0% | $159K+56.3% | $127K+12.3% | $55K-71.3% | $57K+1826.6% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
RGPX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$4.2M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.13), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Regenerex Pharma Inc Ranks
Frequently Asked Questions
No, Regenerex Pharma Inc (RGPX) reported a net loss of $2.5M in fiscal year 2025.
Regenerex Pharma Inc (RGPX) had EBITDA of -$1.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Regenerex Pharma Inc (RGPX) recorded an outflow of $1.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Regenerex Pharma Inc (RGPX) had $1.3M in total assets as of fiscal year 2025, including both current and long-term assets.
Regenerex Pharma Inc (RGPX) invested $662K in research and development during fiscal year 2025.
Regenerex Pharma Inc (RGPX) had a current ratio of 0.13 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Regenerex Pharma Inc (RGPX) had a return on assets of -200.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Regenerex Pharma Inc (RGPX) has negative shareholder equity of -$4.2M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Regenerex Pharma Inc (RGPX) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Regenerex Pharma Inc (RGPX) reported a net loss of $2.5M while operations used $1.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Regenerex Pharma Inc (RGPX) reported an operating loss of $1.8M against $320K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.